Search companies

Live

CLINUVEL PHARMACEUTICALS LIMITED (ASX: CUV)

Health care · News and insights

CUV: $7.38 -2.77% · MC: $375M

Latest CUV announcements

Announcement Insights

CLINUVEL Advances Second Product Review As US Move And Vitiligo Trials Approach

CLINUVEL has moved NEURACTHEL Instant into regulatory review while preparing a US head office move and advancing its vitiligo programme. Filed on October 30 in three EU countries, the dossier begins review of the company’s second pharmaceutical product; approval is not assured, and the process is expected to take 300 days excluding possible pauses. At its November 6 meeting, the company said first Phase III vitiligo results were expected in December and a second study would begin next quarter; the chair corrected the study timing, while the possible Nasdaq listing, ASX delisting and redomiciliation remain under consideration.

Updated 17 Nov 2026, 04:34 PM Sydney time
Share
SourcesChange in substantial holdingChange in substantial holding - UpdatedChair addressManaging Director AddressChair address - amendmentResults of MeetingCLINUVEL files NEURACTHEL Instant dossier
Comments

JPMorgan Lifts CLINUVEL Voting Stake To Nearly 8%

2026-11-17 · Health care

CUV: $7.38 -2.77% · MC: $375M

JPMorgan Chase & Co. and its affiliates increased their relevant interest in CLINUVEL Pharmaceuticals to 7.96% from 6.53%. The notice includes securities lending and client-related interests, so the change should not be read simply as a share purchase.

Updated 2026-11-17 16:20
Share
SourcesChange in substantial holdingChange in substantial holding - Updated
Comments

CLINUVEL Sets US Head Office Move As Shareholders Reject Pay Report

2026-11-06 · Health care

CUV: $7.52 -2.84% · MC: $375M

CLINUVEL says its head office will move to the United States from January 2027, while it is still considering a full Nasdaq listing, ASX delisting and redomiciliation. The chair said the company holds more than A$260 million in cash with no debt, and expects first Phase III vitiligo results in December; the second study is due to begin next quarter. Shareholders rejected the remuneration report, triggering a second strike, while the chair’s amended address corrected the timing of the second study.

Updated 2026-11-06 12:23
Share
SourcesChair addressManaging Director AddressChair address - amendmentResults of Meeting
Comments

CLINUVEL Files NEURACTHEL Dossier With European Regulators

2026-10-30 · Health care

CUV: $7.22 -1.50% · MC: $375M

CLINUVEL has filed for marketing authorisation of NEURACTHEL Instant in three European Union countries, beginning regulatory review of its second pharmaceutical product. Approval could allow launches in up to three initial markets; the review is intended to take 300 days, excluding possible pauses, and the product is not yet approved anywhere.

Updated 2026-10-30 08:36
Share
SourcesCLINUVEL files NEURACTHEL Instant dossier
Comments